Within aging population in the world, the number of dementia patients particularly Alzheimer disease (AD) is increasing (
1). The chief pathological molecule in AD is amyloid β-peptide (Aβ) (
1). On the other hand, non-steroidal anti-inflammatory drugs (NSAID) as firstly introduced in 1960s, was broadly used drug worldly. It was estimated that the annual application of this medicine is over 100 million in the U.S. The benefits of NSAIDs is extensive in medical fields, in which can be applied as pain reliever, and inflammation reducer by inhibiting the prostaglandins (
2). The diseases that were previously examined with NSAIDs include sepsis (
3), cancer, (
4), Parkinson disease (
5), and Alzheimer’s disease (
6). In each of these diseases, the mechanisms of NSAIDs action have been described as follow: the levels of prostacyclin and thromboxane that cause fever, tachycardia, oxygen consumption, and lactic acidosis in patients with sepsis reduces as treated with ibuprofen (
3). NSAIDs in addition, by inhibiting cox-2 hinder the development of many cancer types and therefore, show properties (
4). Neuroprotective role of this drug family especially ibuprofen (IBU) was identified as helpful in reducing neuroinflammation (
5). In general, ibuprofen is a nonsteroidal anti-inflammatory drug effective on prostaglandin-synthase accounts for as one of the most frequent useful fast pain reliever (
7,
8). The approval of this safe drug which could be used for both short-term and long-term treatments was in 1968 in England (
9). In addition, NSAIDs such as ibuprofen claimed to have some positive effects on memory lose in mice with Alzheimer’ disease (AD) through molecular alterations (
6,
10). They act as inhibitors of two isoforms COX-1 and COX-2, the cyclooxygenase enzymes that are involved in AD and are parts of innate immune system producing prostaglandins. Both the two immunoregulators (COX-1 and COX-2) of brain are appropriate targets for neuroinflammation treatments (
11). This is the famous mechanism by which NASIDs are known to be effective (
6). Inhibition of COXs production lead to reduction of Aβ concentration and therefore its impact as the memory decliner hinders (
11). On the other hand, systematic molecular assessment could be beneficial in this sense. In this regard a set of molecules including genes, small RNAs, and proteins could be recognized through high-throughput methods as biomarkers (
12). Gene expression microarray analysis could be helpful in this regard to provide molecular nature understanding of the designated disease (
13). Likewise, pharmacological properties of some drugs could be clearer by large-scale molecular investigations (
14). Here, the gene expression profile of AD in the treated mice with ibuprofen (dosage of 375 ppm) is investigated via protein interactions map to facilitate uncovering of ibuprofen effect on gene expression profile of AD mice.